Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;41(7):845-853.
doi: 10.1111/pace.13369. Epub 2018 Jun 4.

Severe tricuspid regurgitation due to interactions with right ventricular permanent pacemaker or defibrillator leads

Cory R Trankle  1 , Zachary M Gertz  1 , Jayanthi N Koneru  1 , Vigneshwar Kasirajan  2 , Patricia Nicolato  2 , Hem L Bhardwaj  1 , Kenneth A Ellenbogen  1 , Gautham Kalahasty  1
Affiliations
Review

Severe tricuspid regurgitation due to interactions with right ventricular permanent pacemaker or defibrillator leads

Cory R Trankle et al. Pacing Clin Electrophysiol. 2018 Jul.

Abstract

Although thought to be a rare event, permanent pacemakers and implantable cardioverter-defibrillators with right ventricular intracardiac leads have the potential to induce tricuspid valve dysfunction. Adverse lead-valve interactions can take place through a variety of mechanisms including damage at the time of implantation, leaflet pinning, or long-term fibrosis encapsulating the leaflet tissue. Clinical manifestations can display a wide range of severity, as well as a highly variable time span between implantation and hemodynamic deterioration. This review aims to describe the potential pathophysiologic effects of intracardiac device leads on the tricuspid valve, with a focus on ideal diagnostic strategies and treatment options once lead-induced valvular dysfunction is suspected.

Keywords: cardiac device; implantable cardioverter-defibrillator; pacemaker; tricuspid regurgitation; tricuspid valve; tricuspid valve repair; tricuspid valve replacement.

PubMed Disclaimer

References

REFERENCES

    1. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol. 2017;69:2331-2341.
    1. Rogers JH, Bolling SF. The tricuspid valve: Current perspective and evolving management of tricuspid regurgitation. Circulation. 2009;119:2718-2725.
    1. Delling FN, Hassan ZK, Piatkowski G, et al. Tricuspid regurgitation and mortality in patients with transvenous permanent pacemaker leads. Am J Cardiol. 2016;117:988-992.
    1. Mutlak D, Aronson D, Lessick J, Reisner SA, Dabbah S, Agmon Y. Functional tricuspid regurgitation in patients with pulmonary hypertension: Is pulmonary artery pressure the only determinant of regurgitation severity. Chest. 2009;135:115-121.
    1. Lee RC, Friedman SE, Kono AT, Greenberg ML, Palac RT. Tricuspid regurgitation following implantation of endocardial leads: Incidence and predictors. Pacing Clin Electrophysiol. 2015;38:1267-1274.

MeSH terms

LinkOut - more resources